MustGrow: Seasoned Social Impact Financier Barry Palte Appointed To Advisory Board

MustGrow Biologics (CSE: MGRO) this morning announced that it has strengthened its advisory team. The company has appointed seasoned global social impact financier Barry Palte to its advisory team, whom is expected to leverage his deep global relationships in agriculture tech to support the rollout of MustGrow’s mustard derived technology.

Palte has spent his career focusing on impact investing within disruptive companies that have a major impact on the health of both people and the planet. His investment projects must commit explicitly to these beliefs. With MustGrow focused on producing a natural, organic, and science-based solutions for high-value crops, and taking on synthetic chemical producers in the process, the firm is a natural fit for Palte.

Barry Palte has had an extensive career in executive management, with over 35 years worth of experience in management, funds management, investment and investment banking. His experience includes serving as the Global Chairman of the International Association of Investment Bankers, while also being an invited member of Top Tier Impact. Further, he has spent the last 21 years of his career as the founder of globally focused EQ Capital Partners.

"I am delighted to be joining the MustGrow team to assist with their mission of developing and deploying highly effective crop protection solutions that are safe for our natural environment and the consumers and workers who rely on a safe global food system. The world is facing incredible trials at the moment, from financial to medical and environmental. Key to solving these challenges is connecting the right investment capital and partners to the highest impact companies and projects, at speed and on a global basis. I look forward to supporting the passionate and committed MustGrow team with my global networks." 
Barry Palte

In connection with the appointment, MustGrow has issued 650,000 common share purchase warrants. Each warrant is valid for a period of 2 years from the date of issuance, with an exercise price of $0.35 per share.

MustGrow Biologics last traded at $0.39 on the CSE.

FULL DISCLOSURE: MustGrow Biologics Corp is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover MustGrow Biologics Corp on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Leave a Reply